Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Microsoft announced a strategic partnership with Mayo Clinic to develop and deploy a frontier AI model specifically for healthcare, combining Mayo Clinic's clinical expertise with the tech giant's technologies.
Read more here.
Healthcare is evolving faster than ever — driven by digital transformation, AI, new care models, and increasing pressure on health systems to deliver better outcomes with fewer resources.
But innovation only works when the right people come together in the…
Attendees
Sponsors and Exhibitors
Contact us